Home › Companies › XENE

Xenon Pharmaceuticals

XENE Lead: Phase 3 1 Biotech Distilled article ↓

Neurology Small Molecule

Most recent annual filing: 2026-02-26

Pipeline (6 active programs)

azetukalner

XEN1101

Small Molecule Target: Kv7 potassium channel

XEN1701

Small Molecule Target: Nav1.7

Acute Pain Phase 1

XEN1120

Small Molecule Target: Kv7 potassium channel, Kv7

Acute Pain Phase 1

NBI-921355

Small Molecule Target: Nav1.2, Nav1.6

Epilepsy Phase 1 Neurocrine Biosciences

Biotech Distilled coverage (1)

2026-05-02 Xenon Pharmaceuticals (XENE) - Scientific Deep Dive for Azetukalner and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.